HER2-targeted antibody-drug conjugate that binds HER2 and delivers a cytotoxic payload to kill HER2-expressing tumor cells (with potential bystander effect).
HER2‑targeted trastuzumab‑based ADC that binds HER2, is internalized, and releases a cleavable camptothecin (topoisomerase I–inhibiting) payload, causing DNA damage and apoptosis in HER2‑expressing tumor cells with potential bystander effect.
NO
INDIRECT
The ADC binds HER2, is internalized, and releases a camptothecin payload that inhibits topoisomerase I, causing DNA damage and apoptosis in HER2+ cells (with possible bystander effect); topoisomerase I itself is not the targeted antigen.
Chimeric anti-CD20 monoclonal antibody that mediates antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct apoptosis of CD20-positive B cells.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and mediates depletion via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis of CD20-positive cells.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers killing via Fc-mediated ADCC (NK cells/macrophages) and complement-dependent cytotoxicity, and can also induce apoptosis of CD20+ cells.
A full-length bispecific monoclonal antibody (Lunsumio; RO7030816) that binds CD20 on B cells and CD3 on T cells to redirect autologous T-cell cytotoxicity against malignant B cells in indolent B-cell lymphomas.
Humanized full-length bispecific monoclonal antibody that simultaneously binds CD20 on B cells and CD3 on T cells, physically linking T cells to CD20+ malignant B cells. This T-cell engagement triggers TCR-mediated activation, immune synapse formation, cytokine release, and perforin/granzyme-dependent cytotoxicity, leading to apoptosis of CD20-expressing lymphoma cells.
YES
DIRECT
Mosunetuzumab bridges CD3 on T cells and CD20 on B cells, activating T cells to form an immune synapse and kill CD20+ cells via perforin/granzyme-mediated apoptosis.
A full-length bispecific monoclonal antibody (Lunsumio; RO7030816) that binds CD20 on B cells and CD3 on T cells to redirect autologous T-cell cytotoxicity against malignant B cells in indolent B-cell lymphomas.
Humanized full-length bispecific monoclonal antibody that simultaneously binds CD20 on B cells and CD3 on T cells, physically linking T cells to CD20+ malignant B cells. This T-cell engagement triggers TCR-mediated activation, immune synapse formation, cytokine release, and perforin/granzyme-dependent cytotoxicity, leading to apoptosis of CD20-expressing lymphoma cells.
NO
INDIRECT
CD3+ T cells are not the killing target. Mosunetuzumab binds CD3 to activate and redirect T cells, which then kill CD20+ B cells via immune synapse formation and perforin/granzyme-mediated cytotoxicity.
Glycoengineered type II anti‑CD20 IgG1 monoclonal antibody that induces direct B‑cell death and enhances immune effector functions (ADCC/ADCP, some CDC) against CD20‑positive B cells.
Glycoengineered humanized type II anti‑CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them via enhanced FcγRIIIa-mediated ADCC/ADCP and direct (caspase‑independent) cell death, with some complement‑dependent cytotoxicity.
YES
DIRECT
Binds CD20 on B cells, causing direct caspase-independent cell death and recruiting Fc gamma RIIIa–bearing effector cells for ADCC/ADCP; also some complement-dependent cytotoxicity.